Commentary
Volume 12:01, 2024

Journal of Clinical & Medical Genomics

ISSN: 2472-128X
Open Access

Exploring the Interaction between Clspn Gene Polymorphisms: Implications for Health and Disease

Katri Sarvi*

Department of Pathology, University of Helsinki, Helsinki, Finland

Description

Genetic polymorphisms play a significant role in individual variations in health outcomes and disease susceptibility. The CLSPN gene, encoding Claspin protein, is pivotal in the DNA damage response pathway, contributing to genome stability. Polymorphisms in CLSPN have been associated with various diseases, including cancer and neurodegenerative disorders. This article aims to explore the interaction between CLSPN gene polymorphisms and their implications for health and disease, shedding light on potential diagnostic and therapeutic avenues. The CLSPN gene, located on chromosome 1p13.3, encodes the Claspin protein, an essential regulator of the DNA Damage Response (DDR) pathway. Claspin functions as a mediator protein, facilitating the activation of the checkpoint kinase CHK1 in response to DNA damage, thereby orchestrating cell cycle arrest and DNA repair processes. Given its crucial role in maintaining genomic integrity, genetic variations in CLSPN have garnered significant attention for their potential implications in health and disease [1].

Polymorphisms in the CLSPN gene can occur at various loci, influencing gene expression, protein structure, and function. Single Nucleotide Polymorphisms (SNPs) are the most common type of genetic variation observed in CLSPN, with certain variants linked to altered DDR efficiency and disease susceptibility. Notably, SNPs in the promoter region of CLSPN may modulate gene transcription, affecting the abundance of Claspin protein and subsequently impacting cellular responses to DNA damage. Cancer Susceptibility: Several studies have investigated the association between CLSPN polymorphisms and cancer risk. For instance, a meta-analysis revealed that the CLSPN rs1050238 polymorphism is significantly associated with increased susceptibility to breast cancer in certain populations. Similarly, variants in CLSPN have been implicated in colorectal, ovarian, and lung cancers, underscoring the importance of genetic predisposition in cancer development [2,3].

Neurodegenerative disorders: Emerging evidence suggests a potential link between CLSPN polymorphisms and neurodegenerative diseases such as Alzheimer's and Parkinson's. Dysregulation of DDR mechanisms, including impaired Claspin function due to genetic variants, may contribute to neuronal DNA damage accumulation and neuronal loss observed in these conditions. Understanding the genetic basis of neurodegeneration could offer insights into novel therapeutic targets for disease intervention. Cardiovascular Health: The role of CLSPN polymorphisms in Cardiovascular Diseases (CVDs) has also been explored. Variants associated with altered DDR efficiency may influence vascular endothelial function and contribute to atherosclerosis development. Moreover, genetic predisposition mediated by CLSPN polymorphisms could modulate individual responses to therapeutic interventions for CVDs, highlighting the importance of personalized medicine approaches.

Elucidating the functional consequences of CLSPN gene polymorphisms is crucial for understanding their impact on cellular processes and disease pathogenesis. Experimental studies employing cell-based assays, animal models, and functional genomics approaches have provided insights into how specific variants affect Claspin expression, protein stability, and interaction with DDR components. Furthermore, structural modelling and computational analyses offer predictive tools to assess the structural and dynamic changes induced by CLSPN polymorphisms, guiding the design of targeted therapies. The identification of CLSPN polymorphisms associated with disease susceptibility holds promise for clinical applications in risk assessment, early detection, and personalized treatment strategies. Genomic profiling integrating CLSPN variants with other genetic and environmental factors could enhance predictive models for disease prognosis and therapeutic response. Moreover, targeted interventions aimed at restoring DDR efficiency or exploiting synthetic lethal interactions in cancer cells harbouring specific CLSPN variants represent potential avenues for precision medicine approaches [4,5].

Acknowledgement

None.

Conflict of Interest

None.

References

1. *Agarwal, V., G. W. Bell, J. Nam and D. P. Bartel.* "Predicting effective microRNA target sites in mammalian mRNAs." *eLife* 4.
2. Enright, A. J., B. John, U. Gaul and T. Tuschl, et al. "Biology Micro RNA targets in drosophila." *Genome Biol* 5(2003): R1.
3. Rodrigues, Carlos HM, Douglas EV Pires and David B. Ascher. "DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations." *Protein Sci* 30 (2021): 60-69.
4. Varki, A and S. Kornfeld. "Identification of a rat liver alpha-N-acetylglucosaminyl phosphodiesterase capable of removing "blocking" alpha-N-acetylglucosamine residues from phosphorylated high mannose oligosaccharides of lysosomal enzymes." *J Biol Chem* 255 (1980): 8398-8401.
5. Waheed, A., Andrej Hasilik and Kurt von Figura. "Processing of the phosphorylated recognition marker in lysosomal enzymes, characterization and partial purification of a microsomal alpha-N-acetylglucosaminyl phosphodiesterase." *J Biol Chem* 256 (1981): 5717-5721.

***Address for Correspondence:** Katri Sarvi, Department of Pathology, University of Helsinki, Helsinki, Finland, E-mail: katri.sarvikit@helsinki.fi*

Received: 01 January 2024, Manuscript No. JCMG-24-129850 **Editor assigned:** 03 January, 2024, PreQC No. P-129850; **Reviewed:** 17 January 2024, QC No. Q-129850; **Revised:** 23 January 2024, Manuscript No. R-129850; **Published**: 29 January, 2024, DOI: 10.37421/2472-128X.2024.12.261

How to cite this article: Sarvi, Katri. "Exploring the Interaction between Clspn Gene Polymorphisms: Implications for Health and Disease." *J Clin Med Genomics* 12 (2024): 261.